Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 54

Results For "markets"

1112 News Found

Digital Health: An opportunity to increase health equity
Digitisation | April 14, 2023

Digital Health: An opportunity to increase health equity

Clinical Decision Support Systems' huge potential to help ensure that each patient can receive high-quality care; study shows a reduction in diagnostic errors from 24% to 2%


Apitoria Pharma  appoints Dr. Sanjay Chaturvedi as CEO
People | April 06, 2023

Apitoria Pharma appoints Dr. Sanjay Chaturvedi as CEO

Venkat Nageswar Chalasani has been appointed as an Independent Director of Apitoria Pharma with effect from April 4, 2023


Antibody-drug conjugates gain traction in China oncology market, says GlobalData
News | April 04, 2023

Antibody-drug conjugates gain traction in China oncology market, says GlobalData

China is among the top countries reporting a high number of diagnosed prevalent cases for gastric, breast, and bladder cancers among the 16 major markets


Top management changes at IOL Chemicals and Pharmaceuticals
People | April 04, 2023

Top management changes at IOL Chemicals and Pharmaceuticals

Vikas Vij has been appointed as Chief Executive Officer (CEO) of the company


Getinge to boost scalability and deepen healthcare access in India
Medical Device | April 01, 2023

Getinge to boost scalability and deepen healthcare access in India

Getinge has a strong market share in India within several product segments


HSBC acquisition of SVB UK to unleash new opportunities in biotech sector, finds GlobalData
Biotech | April 01, 2023

HSBC acquisition of SVB UK to unleash new opportunities in biotech sector, finds GlobalData

SVB Financial Group and its subsidiaries were involved in over $1.4 billion in total venture financing raised from 2010 to 2022 for drug development


Lupin receives approval from USFDA for Brexpiprazole Tablets
Drug Approval | March 22, 2023

Lupin receives approval from USFDA for Brexpiprazole Tablets

Brexpiprazole Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg, (RLD Rexulti) had estimated annual sales of US $1,575 million in the US (IQVIA MAT December 2022)


Dr. Reddy's divests non-core brands in dermatology to Eris Lifesciences for Rs 275 Cr
News | March 17, 2023

Dr. Reddy's divests non-core brands in dermatology to Eris Lifesciences for Rs 275 Cr

Eris Lifesciences will be assigned the trademark of these brands by Dr. Reddy's for a consideration of Rs. 275 crore